In today’s session SAGE Therapeutics Inc (SAGE) registered an unusually high (316) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious SAGE increase. With 316 contracts traded and 1664 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: SAGE161118C00050000 closed last at: $1.55 or 40.9% up. About 28,545 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 32.06% since March 9, 2016 and is uptrending. It has outperformed by 24.65% the S&P500.
Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on November, 3. They expect $-1.11 earnings per share, down 32.14% or $0.27 from last year’s $-0.84 per share. After $-1.08 actual earnings per share reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.78% negative EPS growth.
SAGE Therapeutics Inc (NASDAQ:SAGE) Ratings Coverage
Out of 9 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 78% are positive. $90 is the highest target while $18 is the lowest. The $65.71 average target is 52.11% above today’s ($43.2) stock price. SAGE Therapeutics has been the topic of 10 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Raymond James given on Tuesday, September 13. H.C. Wainwright initiated SAGE Therapeutics Inc (NASDAQ:SAGE) rating on Thursday, June 23. H.C. Wainwright has “Buy” rating and $56 price target. The stock has “Buy” rating given by Lake Street on Friday, March 11. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) earned “Neutral” rating by Goldman Sachs on Wednesday, March 30. The rating was initiated by BMO Capital Markets with “Outperform” on Wednesday, June 29. JP Morgan maintained the stock with “Buy” rating in Thursday, September 3 report. The company was maintained on Thursday, September 3 by Leerink Swann. The rating was initiated by Chardan Capital Markets with “Sell” on Tuesday, May 24.
According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.51 in Q2 2016. Its down 0.73, from 2.24 in 2016Q1. The ratio is negative, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
State Street has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Jacobs Levy Equity Mgmt holds 0.04% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 58,670 shares. Sabby Limited Liability Corporation holds 0.11% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 68,950 shares. Tiaa Cref Invest Mgmt Ltd owns 88,521 shares or 0% of their US portfolio. Pnc Fincl Group holds 75 shares or 0% of its portfolio. Sphera Funds last reported 0.54% of its portfolio in the stock. Deutsche Commercial Bank Ag reported 417,012 shares or 0.01% of all its holdings. Nationwide Fund has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Citadel Advsr Ltd Liability Co has 0.02% invested in the company for 650,008 shares. Glob X Mngmt Co Limited Liability Company last reported 124 shares in the company. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 4,162 shares. Manufacturers Life Insurance Company The has 18,361 shares for 0% of their US portfolio. Lord Abbett And Co Limited Co, a New Jersey-based fund reported 722,800 shares. Wells Fargo Mn has 0% invested in the company for 27,266 shares. Palo Alto Limited Liability accumulated 417,878 shares or 0.95% of the stock.
Insider Transactions: Since April 19, 2016, the stock had 0 buys, and 6 insider sales for $55.15 million net activity. On Tuesday, July 12 IGUCHI KIMI sold $247,750 worth of the stock or 5,000 shares. Shares for $26.56 million were sold by Third Rock Ventures II – L.P. on Monday, May 16. Shares for $880,000 were sold by Robichaud Albert on Tuesday, July 12. $26.56 million worth of SAGE Therapeutics Inc (NASDAQ:SAGE) was sold by STARR KEVIN P on Monday, May 16. $798,000 worth of SAGE Therapeutics Inc (NASDAQ:SAGE) was sold by Kanes Stephen.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $1.51 billion. The Firm is engaged in developing and commercializing medicines to treat central nervous system disorders. It currently has negative earnings. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
SAGE Company Profile
SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
More notable recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Marketwatch.com with their article: “Sage Therapeutics stock rises 12% after FDA designates drug a ‘breakthrough …” published on September 06, 2016, Prnewswire.com published: “Sage Therapeutics, Inc. – Product Pipeline Review – 2016” on September 27, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) were released by: Valuewalk.com and their article: “SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital” published on April 01, 2016 as well as Valuewalk.com‘s news article titled: “SAGE Therapeutics Inc (SAGE) Overhyped Lead Drug Headed for Failure â€“ Kerrisdale” with publication date: March 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.